Entrada Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $1,950 | $20,558 | $37,398 | $19,570 |
Gross Profit | 850 | 20,558 | 36,406 | 18,670 |
EBITDA | -46,849 | -20,844 | -4,875 | -21,658 |
EBIT | -46,849 | -21,790 | -5,867 | -22,595 |
Net Income | -43,103 | -17,349 | 1,131 | -14,032 |
Net Change In Cash | 1,950 | 20,558 | 37,398 | 19,570 |
Free Cash Flow | -29,764 | -39,651 | -32,240 | -24,905 |
Cash | 72,482 | 67,837 | 101,211 | 78,049 |
Basic Shares | 41,339 | 41,074 | 43,050 | 40,630 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $210,782 | $129,013 | $25,260 | $0 |
Gross Profit | 210,782 | 29,129 | -1,895 | -1,117 |
EBITDA | 47,011 | -321 | -95,353 | -50,010 |
EBIT | 47,011 | -3,162 | -97,248 | -51,127 |
Net Income | 65,626 | -6,685 | -87,457 | -50,072 |
Net Change In Cash | 210,782 | 129,013 | 25,260 | 0 |
Cost of Revenue | 252,019 | |||
Free Cash Flow | -44,715 | 134,189 | -96,673 | -55,442 |
Cash | 101,211 | 67,602 | 45,157 | 291,064 |
Basic Shares | 39,003 | 33,050 | 31,293 | 31,224 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$1.04 |
2025-03-31 | -$0.42 |
2024-12-31 | $0.03 |
